Assessment of Rivaroxaban Plasma Concentration Using Chromogenic Anti‐Xa Assays and UHPLC–MS/MS in Chinese Patients With Atrial Fibrillation
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70088 ↗At a glance
Vergleichsstudie in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Xiao-Qin Liu and 7 co-authors. Institution: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Atrial Fibrillation, Drug Monitoring, Factor Xa Inhibitors, Rivaroxaban. Cited 1 times so far (Crossref); 33 references. Funded by: Shanghai "Rising Stars of Medical Talent" Youth Development Program (Youth Medical Talents-Clinical Pharmacist Program), Shanghai Key Clinical Specialty Projects-Clinical Pharmacy.
Abstract (original language)
Accurate quantification of rivaroxaban concentration is essential in some specific clinical situations. A prospective study was conducted to compare the rivaroxaban concentration measured by Zhenyuan anti‐Xa assay with that by reference methods (ultrahigh performance liquid chromatography with tandem mass spectrometry [UHPLC–MS/MS] and Biophen DiXal) in 243 plasma samples from 182 patients with non‐valvular atrial fibrillation. Zhenyuan anti‐Xa assays demonstrated less bias versus reference methods in samples with concentrations exceeding 50 μg/L compared to those in the < 50 μg/L group. Strong correlations were observed between Zhenyuan anti‐Xa assays and both reference methods (Pearson's correlation coefficient 0.976 and 0.988, respectively). However, Bland–Altman analysis revealed systematic underestimation by Zhenyuan anti‐Xa assays, with mean biases of 41.87 μg/L (vs. UHPLC–MS/MS) and 26.76 μg/L (vs. Biophen DiXal), particularly pronounced at higher levels. Rivaroxaban concentration in patients from clinical settings was with greater variability compared to the expected ranges. Patients taking underdose of rivaroxaban are more likely to have a trough concentration falling below the targeted therapeutic range.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Laboratory Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Pharmacy, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
ORCID profiles: Xiao-Qin Liu
Funding
- Shanghai "Rising Stars of Medical Talent" Youth Development Program (Youth Medical Talents-Clinical Pharmacist Program)
- Shanghai Key Clinical Specialty Projects-Clinical Pharmacy
Cite
APA
Liu, X. Q., Gu, Y., Zhang, Y. F., Shen, W., Gu, Z. C., Zhong, M. K., Ding, H. Y., & Ma, C. L. (2025). Assessment of Rivaroxaban Plasma Concentration Using Chromogenic Anti‐Xa Assays and UHPLC–MS/MS in Chinese Patients With Atrial Fibrillation. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70088
Vancouver
Liu XQ, Gu Y, Zhang YF, Shen W, Gu ZC, Zhong MK, et al. Assessment of Rivaroxaban Plasma Concentration Using Chromogenic Anti‐Xa Assays and UHPLC–MS/MS in Chinese Patients With Atrial Fibrillation. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70088
BibTeX
@article{Liu2025,
author = {Liu, Xiao-Qin and Gu, Yi and Zhang, Yu-Fei and Shen, Wei and Gu, Zhi-Chun and Zhong, Ming-Kang and Ding, Hong-Yan and Ma, Chun-Lai},
title = {Assessment of Rivaroxaban Plasma Concentration Using Chromogenic Anti‐Xa Assays and UHPLC–MS/MS in Chinese Patients With Atrial Fibrillation},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70088}
}
EUVIMED